MNPR · Monopar Therapeutics Inc. · Stock research

Current Thesis

Monopar is a rare-disease/radiopharma small-cap whose tradeable story is ALXN1840, a Phase-3-positive Wilson Disease drug picked up cheaply off AstraZeneca's discard pile in Oct 2024, now heading into a mid-2026 FDA NDA filing. The June 2026 leg is fresh EAN 2026 neurologic data (UWDRS Part III, p=0.006, presented 2026-06-26) stacked on a 6.70M-share float which sent social velocity +367% and RSI to ~84 straight into a congress sell-the-news window. The catalyst is genuine and de-risked; the tape underneath it is late-stage and stretched.

Bullish and bearish views on Monopar Therapeutics Inc.

The model's bull view on Monopar Therapeutics Inc. (MNPR), in brief: ALXN1840 (bis-choline tetrathiomolybdate) Phase 3 FoCus already met its primary endpoint copper mobilization, mean daily AUEC for dNCC over 48 weeks vs standard of care. The bear view: FierceBiotech framed ALXN1840 as retrieved from "AstraZeneca's scrapheap" AZ/Alexion deprioritized it after the acquisition. Both cases follow in full.

Bull Case

• ALXN1840 (bis-choline tetrathiomolybdate) Phase 3 FoCus already met its primary endpoint copper mobilization, mean daily AUEC for dNCC over 48 weeks vs standard of care. License announced 2024-10-24, so this is a de-risked asset rather than a pending binary readout.
• Four positive prints in ~10 weeks: AAN 2026 (April, neurologic benefit vs SoC), publication 2026-05-19 (~50% increase in fecal copper output-to-intake), EASL 2026 (2026-06-01, Phase 2 WD-205, n=29, liver stabilization + neuro gains over 48 wks), EAN 2026 (2026-06-26, UWDRS Part III p=0.006).
• NDA submission to FDA guided for mid-2026 converts the clinical story into a regulatory clock with a near-term trigger. Wilson Disease is an orphan indication; approval would be the first new branded entrant in years.
• Capital-light structure: upfront paid as cash + Monopar equity plus tiered royalties and regulatory/sales milestones; AstraZeneca absorbed the development-history cost while Monopar owns the upside.
• $143.7M cash (as of 2025-09-30) funds operations through Dec 31 2027 including potential ALXN1840 commercial prep no forced raise into the NDA. Last offering Sep 2025 ($91.9M net proceeds).
• 6.70M shares out / ~$587M cap a float this thin gaps violently on any approval, partnership, or designation headline.
• Free optionality in MNPR-101 radiopharma (uPAR-targeted: 101-Zr imaging, 101-Lu / 101-Ac therapy), with 101-Ac moving toward the clinic a second narrative barely in the price.
• Sell-side Strong Buy, average PT $112.62 (~28% above the $87.68 close on 2026-06-26) across ~11 analysts.

Bear Case

• FierceBiotech framed ALXN1840 as retrieved from "AstraZeneca's scrapheap" AZ/Alexion deprioritized it after the acquisition. The FoCus primary endpoint was a copper-mobilization biomarker AUEC, not a hard clinical outcome, and the regulatory path has drawn questions before. An FDA that wants outcome data could refuse-to-file or demand more work.
• The 2026-06-26 move is a thin-float melt-up RSI ~84, social +367% running directly into EAN 2026 (2026-06-27 to 06-30, Geneva). The market-moving readout already hit the wire on the 26th, so the congress itself is a sell-the-news event.
• Stock printed $85.70-$92.26 on 2026-06-26 and faded ~2% after hours; it sits in the upper third of the 52-week $29.18-$105.00 range after a +177% trailing run. Chasing peak retail sentiment on a stretched name is a mean-reversion setup.
• "Mid-2026" NDA timing is soft. A slip into Q4 removes the catalyst clock that justifies the premium and lets the float unwind.
• Single-asset concentration: if ALXN1840 stumbles at FDA, MNPR-101 is years and dollars away from offsetting it.
• A 6.70M float cuts both ways illiquidity amplifies downside gaps as hard as upside.
• Next earnings 2026-08-11; cash-burning microcaps can surprise with financing/dilution language even with runway booked to 2027.

Setup & Price Structure

• Last $87.68 (2026-06-26 close), ~-2% after hours (~$86). Intraday 2026-06-26 range $85.70-$92.26.
• 52-week range $29.18-$105.00; trading ~16% below the high after a parabolic June leg.
• RSI ~84 is overbought; retail/social velocity +367% (3-14d). The fundamentals are de-risked but the tape is in a blow-off.
• This is not a fresh-entry zone: the move is extended into a known event whose readout already printed. A disciplined entry waits for the leg to base a higher low or a pullback that holds a prior breakout shelf instead of buying RSI 84 into a congress.
• With a 6.70M float, intraday stop logic gets whipsawed; any engagement here is a probe sized off a weekly-close rule, not intraday noise.

Catalyst Calendar (next 30 days)

• ~2026-07 (mid-2026, est.) ALXN1840 NDA submission to FDA. The real binary, converting the data into a regulatory clock; not precisely dated, so watch the IR wire for "submitted/accepted."
• 2026-08-11 Q2 2026 earnings (cash burn, NDA progress, any financing language). Just outside 30 days but on the radar.

Elapsed catalysts

• 2026-06-27 to 06-30 EAN 2026 Congress, Geneva (Palexpo). New ALXN1840 neurologic/global-benefit analyses; the key data already released 2026-06-26 (UWDRS Part III p=0.006). Sell-the-news risk is live now. _(passed 18d ago)_

What Would Change Our Mind

• Bullish escalation: confirmed NDA acceptance/filing (not just "submitted"), FDA orphan or priority-review designation, or an ALXN1840 ex-US partnership any re-rates the float on substance, not sentiment.
• Re-entry on structure: once this leg cools, a higher low that holds a prior consolidation shelf on renewed volume is a clean base to engage rather than chasing the vertical.
• Thesis break: an FDA refuse-to-file or demand for new outcome trials; the NDA slipping past Q3 2026; or a surprise dilutive raise that signals the 2027 runway was optimistic.
• Theme rolling over: social velocity collapsing while price loses the June base on rising volume = the squeeze is finished.

Correlation Notes

• Trades on its own clinical-event clock far more than the broad biotech tape, but a hostile XBI/IBB regime compresses speculative microcap multiples and thin-float names take the worst of it.
• No clean Wilson Disease pure-play comp (Alexion legacy, Orphalan/Cuprior, Wilson Therapeutics history) ALXN1840 read-throughs are idiosyncratic.
• Radiopharma optionality (MNPR-101, uPAR) loosely shadows the radioligand theme (Lantheus, RayzeBio/BMS, Novartis Pluvicto) but is too early to move on peer headlines.
• Rate-sensitive like all long-duration, cash-burning biotech: a risk-off / tightening macro lifts the discount rate on a 2027-plus commercial story.